Dakota Wealth Management Sells 836 Shares of Organon & Co. (NYSE:OGN)

Dakota Wealth Management cut its holdings in shares of Organon & Co. (NYSE:OGN) by 1.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 49,758 shares of the company’s stock after selling 836 shares during the period. Dakota Wealth Management’s holdings in Organon & Co. were worth $742,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. American Century Companies Inc. lifted its holdings in Organon & Co. by 76.4% in the second quarter. American Century Companies Inc. now owns 29,509 shares of the company’s stock valued at $611,000 after buying an additional 12,782 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of Organon & Co. by 6.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 166,835 shares of the company’s stock valued at $3,453,000 after purchasing an additional 9,755 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Organon & Co. by 23.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,407,915 shares of the company’s stock worth $49,843,000 after purchasing an additional 463,216 shares during the period. Renaissance Technologies LLC bought a new stake in Organon & Co. in the second quarter valued at about $1,120,000. Finally, Mercer Global Advisors Inc. ADV lifted its stake in Organon & Co. by 1.8% in the second quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock valued at $674,000 after buying an additional 546 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $15.97 on Friday. The stock’s fifty day simple moving average is $15.36 and its 200 day simple moving average is $18.09. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The company has a market capitalization of $4.11 billion, a PE ratio of 3.17, a PEG ratio of 0.87 and a beta of 0.76. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the business earned $0.78 EPS. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. On average, research analysts predict that Organon & Co. will post 3.82 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were issued a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 7.01%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Analyst Ratings Changes

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $21.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.